Since TDP-43 is deposited in protein aggregates in neurons and glia in > 96% of ALS cases, the modulation of ciRNAs biogenesis by targeting Dbr1 might represent a therapeutic strategy for ALS and other related TDP-43 proteinopathies. The gene discussed is TARDBP; the disease is proteostasis deficiencies.